Clinical Trial Update: Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial (Can-Prevent-Lung) evaluating canakinumab for lung cancer prevention, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Status: RECRUITING